FDA-APPROVED PRODUCT THERAPY AREAS

FDA-approved Product

Therapy Areas

Sanofi has a long-standing commitment to the development of treatments for patients with multiple sclerosis (MS). Since 2012, it has delivered two therapies to treat patients with relapsing forms of MS.

Educational Resources

Multiple Sclerosis

Multiple Sclerosis: Disease State Overview
A presentation providing an overview of MS and its burden on patients, including physical disability and cognitive impairment. The presentation focuses on disease progression, which is independent of relapses and inflammation, and the mechanisms and markers underlying disease progression in MS.

Disability Accumulation in Multiple Sclerosis (Infographic)
Discusses the furthering of disability accumulated in multiple sclerosis due to inflammation and demyelination, presenting data on continued progression independent of relapse activity despite inflammation suppression by disease modifying therapies. Additionally, introduces smoldering disease as a key unaddressed component of MS and its role in the disease course.